Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sarcoma, Kaposi 3Myeloproliferative Disorders 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Acquired Immunodeficiency Syndrome 2Plasmablastic Lymphoma 1Optic Nerve Glioma 1Neurofibromatosis 1 1Myelodysplastic Syndromes 1Multi-centric Castleman's Disease 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myelomonocytic, Chronic 1Epstein-Barr Virus Infections 1Central Nervous System Neoplasms 1Burkitt Lymphoma 1

Interventions

liposomal doxorubicin 2Zidovudine 2Valganciclovir 2tocilizumab 1tanespimycin 1pomalidomide 1ibrutinib 1Vincristine 1Sirolimus 1Rituximab 1Prednisone 1Interferon-alpha 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Etoposide 1Doxorubicin 1Cyclophosphamide 1Bortezomib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multi-centric Castleman's Disease × pomalidomide × Clear all
NCT02659930 2026-06-04

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
62 enrolled
Sarcoma

Multi-centric Castleman's Disease, Acquired Immunodeficiency Syndrome, Sarcoma, Kaposi

Data powered by HemOnc (CC BY 4.0) Colophon âš¡